EC - Merck's Keytruda + chemo combo OK'd in Europe for esophageal/gastric cancer

The European Commission ((EC)) has approved Merck's (MRK) Keytruda in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with esophageal cancer or HER2-negative gastroesophageal junction ((GEJ)) adenocarcinoma in adults whose tumors express PD-L1. This approval is based on results from Phase 3 KEYNOTE-590 trial, in which KEYTRUDA plus 5-fluorouracil (5-FU) and cisplatin demonstrated statistically significant improvements in overall survival and progression-free survival compared with 5-FU and cisplatin alone.

For further details see:

Merck's Keytruda + chemo combo OK'd in Europe for esophageal/gastric cancer